1. Chatal JF, Kraber-Bodere F, Bodet-Milin C, Rousseau C. Therapeutic immunoconjugates. Which cytotoxic payload: chemotherapeutic (ADC) or radionuclide (ARC) ? Curr Cancer Therapy Rev. 2016;12:54.
2. Siegel JA, Pawlyk DA, Lee RE, Sasso NL, Horowitz JA, Sharkey RM, et al. Tumor, red marrow, and organ dosimetry for 131I-labeled anti-carcinoembryonic antigen monoclonal antibody. Cancer Res. 1990;50:1039s–42s.
3. Bardiès M, Bardet S, Faivre-Chauvet A, Peltier P, Douillard JY, Mahé M, et al. Bispecific antibody and iodine-131-labeled bivalent hapten dosimetry in patients with medullary thyroid or small-cell lung cancer. J Nucl Med. 1996;37:1853–9.
4. Zanzonico P. Radioimmunotherapy of micrometastases: a continuing evolution. J Nucl Med. 1992;33:2180–3.
5. DeNardo GL, Schlom J, Buchsbaum DJ, Meredith RF, O’Donoghue JA, Sgouros G, et al. Rationales, evidence, and design considerations for fractionated radioimmunotherapy. Cancer. 2002;94:1332–48.